{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"study_type":["Cancer Genomics"],"full_dataset_link":["https://ega-archive.org/studies/EGAS00001005596"],"host":["EGA"],"description":["EGA study EGAS00001005596"],"dataset_title":["Exome and RNA sequencing of pancreatic cancer biopsies and PDX models"],"repository":["EGA"],"category":["restricted"],"description_synonyms":["mismatch repair cancer syndrome 1, mismatch repair cancer syndrome 3, mismatch repair cancer syndrome 2, mismatch repair cancer syndrome 4, Biological Markers, Viral Marker, MMRCS1, Surrogate Endpoints, Activity, HSN1E, 2410041A17Rik, Laboratory, ACTG, Heterograft, ACTE, Mus domesticus, Biochemical, Endpoint, CASP-14, fs(1)M34, TRANSPL HETEROL, nog1, MMRCS2, Tumor, MMRCS3, Serum, 2-oxo-3-azaglutaric acid, MMRCS4, House Mouse, csp2, Act5, brl, Pancreatic Neoplasm, CNS tumors with familial polyposis of the colon, Intervention Study., l(1)G0420, DmelCG12051, Laboratory Markers, Ca tail of pancreas, Ca head of pancreas, Interleukin II, PDCD1L1, IL-2, Biological, HEL-176, Mismatch Repair Cancer Syndrome, CG4601, RU-49637, B7-H1, Interleukine 2, A, Programmed death ligand 1, C, cyt5C, Gene Expressions, Man (Taxonomy), aldesleukin, Biopsies, DHO, SYM1, CG18572, Brain Tumor-Polyposis Syndrome 1, Swiss Mice, Pancreatic Cancers, Lymphocyte Mitogenic Factor, SYNS1, Immune, Xenotransplantations, Markers, malignant neoplasm, act 42A, Viral Markers, Ac5C, T-Cell Stimulating Factor, CG4027, ACT, TG, Act, Malignancies, Lymphoid, house mouse, CXXC finger protein 9, Pancreatic Acinar Carcinomas, PDL1, RU 49637, pancreatic tumour, pancreas neoplasm, Tumors, Carcinoma, Ligand, Viral, l(1)G0330, Surrogate Endpoint, Actin/BAP47, CTE-II, malignant neoplasm of body of pancreas, Modern, AACT, familial, mouse, CTE-IIa, act, Ach1, hBACH, mismatch repair cancer syndrome, ACH1, Biochemical Markers, LACH1, Biologic Marker, results, Expanded, T Cell Growth Factor, act42A, glioma-polyposis syndrome, GIG25, Benign, NOG, Ro-23-6019, PDCD1LG1, Su(b), Alpha-1-antichymotrypsin His-Pro-less, Marker, 1270, AFFX-Dros-ACTIN_M_r_at, GIG24, Mini-ICE, B7-H, DFNA26, actin, pancreatic carcinoma, Lymphoid Cell, Pancreatic, brain tumor-polyposis syndrome, nog-A, Cancer of the Pancreas, LACH, Heterologous Transplantations, GAT, DFNA20, MMR Deficiency, Carcinomas, Xenograft, Mus musculus, B7 homolog 1, ADCADN, MMRCS, Xenotransplantation, Cancer of Pancreas, Immunotherapies, DmelCG4027, UNQ203/PRO229, Caspase-14 subunit p10, Ro 236019, End Points, Transplantation, malignant neoplasm of head of pancreas, mice, DNA (cytosine-5-)-methyltransferase 1, l(1)G0117, Swiss Mouse, expanded, Ex, Ro-236019, initiation, Benign Neoplasms, Actin, Caspase-14 subunit p19, Xenografts, Immunologic, Laboratory Marker, MICE, Pancreas, beta-actin/Bap47, human, Pancreatic Acinar Carcinoma, Malignant Neoplasms, domesticus, l(1)G0486, l(1)G0245, actin5C, l(1)G0009, Ca body of pancreas, Patient, enlarged, Biochemical Marker, ACTL3, T-cell growth factor, Lach1, Cells, Ro236019, Turcot syndrome, l(2)ey, Mouse, PNCA, other neoplasm, BACH, Acinar Carcinomas, l(1)Ab, big, 3.4.22.-, Act5c, Thymocyte Stimulating Factor, l(1)G0010, human being, Mismatch Repair Deficiency, Stromal, Clinical Markers, Clinical Marker, Neoplasms, infiltrating, Benign Neoplasm, Pancreas Cancer, ACT5C, Gene, CG12051, mini-ICE, pancreas, Serpin A3, Transplantations, Malignant, Bach, Pancreas Cancers, heterologous transplantation, Human, Surrogate End Points, l(1)G0025, Surrogate Markers, Aim, large, AIM, CNS tumors with Familial polyposis of the colon, DmelCG4114, Homo sapiens, House, Pancreatic Cancer, Stromal Cell, Ro 23 6019, MMR deficiency, Mus musculus domesticus, Pancreatic Acinar, Cell growth-inhibiting gene 24|25 protein, Carrying, Mice, Man, Pancreatic Carcinomas, CD274, DNMT1, study, Biomarker, act5C, Clinical, Malignancy, DNMT1_HUMAN, Swiss, Pancreatic Carcinoma, malignant tumors of the central nervous system associated with familial polyposis of the colon, Acinar Carcinoma, ligand, BRWS2, Biological Marker, Heterografts, Interleukin 2, PD-L1, malignant tumours of the central nervous system associated with familial polyposis of the colon, Expressions, man, noggin-1, fs(1)829, Neoplasias, API6, Act42a, anon-EST:fe2D2, Immunologic Markers, 1700027G07Rik, Oxaloglycine, Clients, DmelCG18572, great, IL2, Expression, T11, Immunologic Marker, Act-5C, Cte-II, Heterologous, Lymphocyte, Biologic, mismatch repair deficiency, Cancer, DNA MTase HsaI, DNA (cytosine-5)-methyltransferase 1, l(1)G0177, 42A, data, CPS, Malignant Neoplasm, pancreatic neoplasm, Serum Markers, DNMT, CG4114, dJ393D12.2, End Point, CNS tumours with familial polyposis of the colon, MCMT, Client, Pancreas Neoplasm, Cell, Immune Marker, MT, XENOTRANSPL, CAD, TCGF, Mus, Surrogate End Point, beta-actin, DNA methyltransferase HsaI, M32055, Neoplasm, Act42, PDCD1 ligand 1, ACTA3, Lymphoid Cells, Biologic Markers, CXXC9, B7H1, l(1)G0079, malignant neoplasm of tail of pancreas, pancreatic tumor, primary cancer, Serum Marker, CT-2, Mitogenic Factor, Surrogate, PYR1, VSCM, RU49637, Endpoints, act 5C, T-Cell Growth Factor, HETEROL TRANSPL, House Mice, patient, Cancers, malignant tumor, CXXC-type zinc finger protein 9, Surrogate Marker, oxalylglycine, Laboratory Mice, l(2)01270, childhood cancer syndrome, Modern Man, DRORUD, T Cell Stimulating Factor, BAP47, ACTSG, Pancreas Neoplasms, General activity, Laboratory Mouse, Bap47, Neoplasia, CLEC2C, Actin5C, m.HsaI, Immune Markers"],"name_synonyms":["Therapy, Carcinoma, Neoplasms, malignant neoplasm of body of pancreas, pancreatic neoplasm, familial, Pancreas Cancer, pancreas, Pancreas Cancers, Pancreas Neoplasm, Pancreatic Neoplasm, Ca tail of pancreas, Ca head of pancreas, KIAA0012, Pancreatic Cancer, heredity, TEMPERATURE-INDUCED LIPOCALIN, Neoplasm, Pancreatic Acinar, pancreatic carcinoma, Pancreatic, Cancer of the Pancreas, Pancreatic Carcinomas, Carcinomas, treatment, malignant neoplasm of tail of pancreas, pancreatic tumor, Cancer of Pancreas, Pancreatic Carcinoma, malignant neoplasm of head of pancreas, Acinar Carcinoma, Cancers, Pancreatic Cancers, Treatments, Pancreas, ATTIL, Pancreatic Acinar Carcinoma, temperature-induced lipocalin, pancreas neoplasm., K21L19.9, Therapeutic, Ca body of pancreas, disease management, Therapies, Treatment, K21L19_9, PNCA, Pancreas Neoplasms, Pancreatic Acinar Carcinomas, Acinar Carcinomas, pancreatic tumour, Cancer"],"additional_accession":[]},"is_claimable":false,"name":"Genetics and therapeutic responses to TIL therapy of pancreatic cancer PDX models","description":"Pancreatic cancer is the 7th leading cause of cancer-related deaths worldwide. Checkpoint immunotherapy has not yet showed encouraging results in pancreatic cancer possibly owing to a poor immunogenicity and/or an immune suppressive microenvironment. The aim of this study was to develop patient-derived xenografts (PDX) models and to assess if autologous tumor-infiltrating lymphocytes (TILs) would have anti-tumoral activity in pancreatic cancer. Tumor biopsies from 29 patients were subcutaneously transplanted into NOG mice. Tumor growths were confirmed in 11 out of 29 transplantations. The PDX tumors histologically resembled their original biopsies, but since stromal cells in the PDX model tumors were from mouse, their gene expression differed from the original biopsies. Immune checkpoint ligands other than PD-L1 were expressed in pancreatic cancers but PD-L1 was rarely expressed. One of the three tumors that did express PD-L1 was an adenosquamous cancer and another had a mismatch repair deficiency. TILs were expanded from six tumors and were injected into NOG or human interleukin-2 transgenic-NOG (hIL2-NOG) mice carrying PDX tumors. Regression of tumors could be verified in hIL2-NOG mice in 3 of the 6 PDX models treated with autologous TILs, including the adenosquamous PDX model. In conclusion, PDX models of pancreatic cancer can be used to learn more about tumor characteristics and biomarkers, and to evaluate responses to ACT and combination therapies. The major benefit of the model is that modifications of T cells can be tested in an autologous humanized mouse model to gain preclinical data to support the initiation of a clinical trial.","dates":{"updated":"2021-11-08 09:42:56"},"accession":"EGAS00001005596","cross_references":{"TAXONOMY":["9606"],"EGA":["EGAD00001008113","EGAC00001002305"]}}